FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jeanenne Nelson

Research Profile

Chemicals & Drugs

Concepts & Ideas

Disorders

Geographic Areas

United States

Co-author Network

Publications

TOP 3
Thao T Vo; Jeanenne J Nelson
Cardiovascular events in cancer patients treated with highly or moderately emetogenic chemotherapy: results from a population-based study.
Haojie Li; Amit Shukla; Louise Watson; Elizabeth Hodgson; Jeanenne J Nelson
Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis.
Ida J Hatoum; Nancy R Cook; Jeanenne J Nelson; Kathryn M Rexrode; Eric B Rimm
Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jeanenne Nelson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Thao T Vo; Jeanenne J Nelson
Cardiovascular events in cancer patients treated with highly or moderately emetogenic chemotherapy: results from a population-based study.
Journal of cancer epidemiology 2012;2012():529357.
2012: Haojie Li; Amit Shukla; Louise Watson; Elizabeth Hodgson; Jeanenne J Nelson
Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis.
Journal of cancer epidemiology 2012;2012():291704.
2011: Ida J Hatoum; Nancy R Cook; Jeanenne J Nelson; Kathryn M Rexrode; Eric B Rimm
Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women.
American heart journal 2011;161(3):516-22.
2010: Ida J Hatoum; Frank B Hu; Jeanenne J Nelson; Eric B Rimm
Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes.
Diabetes 2010;59(5):1239-43.
2010: Muriel J Caslake; Chris J Packard; Michele Robertson; Josephine Cooney; Jeanenne J Nelson; Ian Ford; Allan Gaw; J Wouter Jukema; Peter W Macfarlane; David J Stott; James Shepherd
Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Atherosclerosis 2010;210(1):28-34.
2010: Nancy Swords Jenny; Cam Solomon; Mary Cushman; Russell P Tracy; Jeanenne J Nelson; Bruce M Psaty; Curt D Furberg
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study.
Atherosclerosis 2010;209(2):528-32.
2010: Ida J Hatoum; Jeanenne J Nelson; Nancy R Cook; Frank B Hu; Eric B Rimm
Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease.
The American journal of clinical nutrition 2010;91(3):786-93.
2009: Takeki Suzuki; Cam Solomon; Nancy Swords Jenny; Russell Tracy; Jeanenne J Nelson; Bruce M Psaty; Curt D Furberg; Mary Cushman
Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study.
Circulation. Heart failure 2009;2(5):429-36.
2008: Margaretha Persson; Göran Berglund; Jeanenne J Nelson; Bo Hedblad
Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden.
Atherosclerosis 2008;200(1):191-8.
2008: Sander J Robins; Dorothea Collins; Jeanenne J Nelson; Hanna E Bloomfield; Bela F Asztalos
Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(6):1172-8.
2008: Curt D Furberg; Jeanenne J Nelson; Cam Solomon; Mary Cushman; Nancy Swords Jenny; Bruce M Psaty
Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study.
Journal of the American Geriatrics Society 2008;56(5):792-9.
2007: Matthew A Allison; Julie O Denenberg; Jeanenne J Nelson; Loki Natarajan; Michael H Criqui
The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients.
Journal of vascular surgery 2007;46(3):500-6.
2007: Michael B Fowler; Sandra R Lottes; Jeanenne J Nelson; Mary Ann Lukas; Edward M Gilbert; Barry Greenberg; Barrie Massie; William T Abraham; Joseph A Franciosa
Beta-blocker dosing in community-based treatment of heart failure.
American heart journal 2007;153(6):1029-36.
2007: Margaretha Persson; Bo Hedblad; Jeanenne J Nelson; Göran Berglund
Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.
Arteriosclerosis, thrombosis, and vascular biology 2007;27(6):1411-6.
2007: Barrie Massie; Jeanenne J Nelson; Mary Ann Lukas; Barry Greenberg; Michael B Fowler; Edward M Gilbert; William T Abraham; Sandra R Lottes; Joseph A Franciosa
Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice.
The American journal of cardiology 2007;99(9):1263-8.
2007: Margaretha Persson; Jan-Ake Nilsson; Jeanenne J Nelson; Bo Hedblad; Göran Berglund
The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort.
Atherosclerosis 2007;190(2):388-96.
2007: William T Abraham; Barrie Massie; Mary Ann Lukas; Sandra R Lottes; Jeanenne J Nelson; Michael B Fowler; Barry Greenberg; Edward M Gilbert; Joseph A Franciosa
Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registry.
Congestive heart failure (Greenwich, Conn.) 2007;13(1):16-21.
2007: Beth D Weatherley; Jeanenne J Nelson; Gerardo Heiss; Lloyd E Chambless; ALBERT SHARRETT; F Javier Nieto; Aaron R Folsom; Wayne D Rosamond
The association of the ankle-brachial index with incident coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study, 1987-2001.
BMC cardiovascular disorders 2007;7():3.
2006: Barry Greenberg; Sandra R Lottes; Jeanenne J Nelson; Mary Ann Lukas; Michael B Fowler; Barrie Massie; William T Abraham; Edward M Gilbert; Joseph A Franciosa
Predictors of clinical outcomes in patients given carvedilol for heart failure.
The American journal of cardiology 2006;98(11):1480-4.
2006: Joseph A Franciosa; Jeanenne J Nelson; Mary Ann Lukas; Sandra R Lottes; Barrie Massie; Michael B Fowler; Barry Greenberg; Edward M Gilbert; William T Abraham
Heart failure in community practice: relationship to age and sex in a beta-blocker registry.
Congestive heart failure (Greenwich, Conn.) 2006;12(6):317-23.
2006: Andrew Zalewski; Jeanenne J Nelson; Lisa Hegg; Colin H Macphee
Lp-PLA2: a new kid on the block.
Clinical chemistry 2006;52(9):1645-50.
2005: Andrew Zalewski; Colin H Macphee; Jeanenne J Nelson
Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis.
Current drug targets. Cardiovascular & haematological disorders 2005;5(6):527-32.
2005: Colin H Macphee; Jeanenne J Nelson; Andrew Zalewski
Lipoprotein-associated phospholipase A2 as a target of therapy.
Current opinion in lipidology 2005;16(4):442-6.
2005: Colin H Macphee; Jeanenne J Nelson
An evolving story of lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular risk prediction.
European heart journal 2005;26(2):107-9.
2004: Joseph A Franciosa; Barrie Massie; Mary Ann Lukas; Jeanenne J Nelson; Sandra R Lottes; William T Abraham; Michael Fowler; Edward M Gilbert; Barry Greenberg
Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry.
American heart journal 2004;148(4):718-26.
2004: Bernard R Chaitman; Sandra L Skettino; John O Parker; Peter Hanley; Jaroslav Meluzin; Jerzy Kuch; Carl J Pepine; Whedy Wang; Jeanenne J Nelson; David A Hebert; Andrew A Wolff
Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
Journal of the American College of Cardiology 2004;43(8):1375-82.
2000: Joseph A Franciosa; William T Abraham; M Fowler; Edward M Gilbert; Barry Greenberg; Barrie Massie; T Chen; Mary Ann Lukas; Jeanenne J Nelson
Rationale, design, and methods for a Coreg (carvedilol) Heart Failure Registry (COHERE). COHERE Participant Physicians.
Journal of cardiac failure 2000;6(3):264-71.